|Presented by:||Michael Kirmiz, Senior Scientist, Bio-Rad Laboratories, Inc.|
Session 1: March 15, 2023, at 9 AM, U.S. Pacific time
(5 PM, Central European time) Session 2: March 15, 2023, at 10 PM U.S. Pacific time
(March 16, 2023 at 1 PM, Singapore time)
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows. Nonviral methods, such as electroporation, represent a potentially safer and less challenging approach for generating CAR T cells. Flexible, high throughput technologies such as flow cytometry can greatly assist in reducing the challenges of CAR-T workflows.
In this webinar, we describe the generation of anti-CD19 CAR T cells in an mRNA electroporation–based CAR T-cell workflow optimized for efficiency and viability. See how CAR transfection efficiencies as high as ~70 and ~90% in primary and immortalized human T cells, respectively, and a viability of ~60% in primary human T cells, were achieved. These data highlight the utility of the Gene Pulser Xcell Electroporation System for generating CAR T cells via mRNA electroporation and the ZE5 Cell Analyzer for expression and analysis.Watch Webinar